Proqr Therapeutics B.V. (PRQR)

[elbiatcho1]

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=521316

Generic Name: antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA
Trade Name: N/A
Date Designated: 05/25/2016
Orphan Designation: Treatment of Leber's congenital amaurosis.
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Sponsor: ProQR Therapeutics IV B.V.
24 Darwinweg
Leiden

The sponsor address listed is the last reported by the sponsor to OOPD.

Orphan drug designation means that the sponsor qualifies for certain benefits but it does not mean the drug is safe and effective and legal to manufacture and market in the United States.

https://en.wikipedia.org/wiki/Orphan_drug